Niagen Bioscience/$NAGE
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Niagen Bioscience
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Ticker
$NAGE
Sector
Primary listing
Employees
104
Headquarters
Website
NAGE Metrics
BasicAdvanced
$527M
28.01
$0.23
2.29
-
Price and volume
Market cap
$527M
Beta
2.29
52-week high
$14.69
52-week low
$5.16
Average daily volume
932K
Financial strength
Current ratio
4.122
Quick ratio
3.225
Long term debt to equity
2.939
Total debt to equity
4.323
Profitability
EBITDA (TTM)
20.079
Gross margin (TTM)
63.89%
Net profit margin (TTM)
16.38%
Operating margin (TTM)
15.48%
Effective tax rate (TTM)
3.87%
Revenue per employee (TTM)
$1,200,000
Management effectiveness
Return on assets (TTM)
15.60%
Return on equity (TTM)
38.90%
Valuation
Price to earnings (TTM)
28.013
Price to revenue (TTM)
4.139
Price to book
7.44
Price to tangible book (TTM)
7.47
Price to free cash flow (TTM)
24.41
Free cash flow yield (TTM)
4.10%
Free cash flow per share (TTM)
0.27
Growth
Revenue change (TTM)
36.04%
Earnings per share change (TTM)
1,093.80%
3-year revenue growth (CAGR)
21.92%
10-year revenue growth (CAGR)
19.00%
3-year earnings per share growth (CAGR)
-7.76%
10-year earnings per share growth (CAGR)
12.56%
What the Analysts think about NAGE
Analyst ratings (Buy, Hold, Sell) for Niagen Bioscience stock.
NAGE Financial Performance
Revenues and expenses
NAGE Earnings Performance
Company profitability
NAGE News
AllArticlesVideos
Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)
Business Wire·4 weeks ago
Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID
Business Wire·4 weeks ago
Niagen Bioscience Announces $10 Million Share Repurchase Program
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Niagen Bioscience stock?
Niagen Bioscience (NAGE) has a market cap of $527M as of December 12, 2025.
What is the P/E ratio for Niagen Bioscience stock?
The price to earnings (P/E) ratio for Niagen Bioscience (NAGE) stock is 28.01 as of December 12, 2025.
Does Niagen Bioscience stock pay dividends?
No, Niagen Bioscience (NAGE) stock does not pay dividends to its shareholders as of December 12, 2025.
When is the next Niagen Bioscience dividend payment date?
Niagen Bioscience (NAGE) stock does not pay dividends to its shareholders.
What is the beta indicator for Niagen Bioscience?
Niagen Bioscience (NAGE) has a beta rating of 2.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.